
<DOC>
<DOCNO>WT02-B19-4</DOCNO>
<DOCOLDNO>IA092-000988-B014-311</DOCOLDNO>
<DOCHDR>
http://www.cytrx.com:80/prstock.htm 206.216.36.35 19970110093827 text/html 6135
HTTP/1.0 200 OK
Date: Friday, 10-Jan-97 09:41:11 GMT
Server: WebSite/1.1
Allow-ranges: bytes
Accept-ranges: bytes
Content-type: text/html
Last-modified: Friday, 03-Jan-97 17:17:04 GMT
Content-length: 5920
</DOCHDR>
<HTML>

<HEAD>

<TITLE>October Press Release</TITLE>


</HEAD>

<BODY background=/icons/wrich/bg.gif>

<table width=95%><tr>
<td align=left>	
	<img src=/icons/cytrx.48pt.gif>
	</td>
<td align=right>
	<img src=/icons/multiopp.gif>
	</td>
</tr></table>
<img src=/icons/wrich/redline.gif>

<P>


<P>
<B><FONT SIZE=4 >CYTRX CORPORATION ANNOUNCES
1996 NINE MONTH RESULTS
</FONT></B>
<P>

<B>Atlanta, Georgia, October 23,
1996<BR>
</B>
<P>
CytRx Corporation (NASDAQ: CYTR)
today announced a net loss of $1.1 million ($.15 per share) for
the three months ended September 30, 1996 versus a loss of $2.0
million ($.25 per share) reported in 1995.  For the nine months
ended September 30, 1996 the company's net loss was $3.6 million
($.46 per share) versus $8.7 million ($1.10 per share) in 1995.
 As of September 30, 1996 CytRx had consolidated cash and short-term
investments of $19.4 million.

<P>
“We continue to make solid progress,”
commented Jack J. Luchese, CytRx president and chief executive
officer. “We are moving ahead with plans to begin an advanced
human clinical trial to study RheothRx&reg;<I><SUB>pf,</SUB></I>
in early 1997.  This trial will be focused on confirming positive
results previously seen in patients suffering from the acute crisis
of sickle cell disease.”

<P>
Luchese added, “Also, our Vetlife
subsidiary recently became the exclusive U.S. supplier of Compudose
cattle growth promotant products for Eli Lilly's Elanco Animal
Health division.  This establishes Vetlife's presence in the beef
productivity market.  On January 1, 1997, Vetlife will become
the exclusive distributor for the new line of Component brand
cattle growth implants, manufactured by Ivy Laboratories, Inc.”


<P>
CytRx was actively purchasing its
own stock during the third quarter.  The company has now repurchased
approximately 351,000 shares which represents 4.4% of previously
outstanding shares.  Noted Luchese, “We feel CytRx stock
is a bargain at current levels, and we are taking advantage of
this opportunity.”

<P>
CytRx's mission is to develop and
commercialize high value human therapeutics while capitalizing
on other opportunities through its wholly-owned subsidiaries.
 CytRx's RheothRx<I><SUB>pf</SUB></I> is being developed to treat
acute sickle cell crisis and other vascular diseases.  Vaxcel,
Inc. is developing Optivax&#174; to improve vaccine effectiveness.
 Vetlife, Inc. is developing products to enhance food animal growth.
 Proceutics, Inc. provides high quality preclinical development
services to the pharmaceutical industry.
<BR>
<P>
<CENTER>CytRx Corporation and Subsidiaries<BR>
Condensed Consolidated Statements Operations<BR>
(Amounts in Thousands except Per Share Data)<BR>
</CENTER>
<BR>
<BR>
<BR>
<P>
<CENTER><TABLE CELLPADDING=2 CELLSPACING=6 BORDER=0>
<TR>
<TD></TD>
   <TD ALIGN=center COLSPAN=2><B>Three Months Ended<BR>September 30</B><HR>
</TD> 
   <TD ALIGN=center COLSPAN=2><B>Nine Months Ended<BR>September 30</B><HR>
</TD>
<TR ALIGN="right">
   <TD></TD>
   <TD><B>1996</B></TD>
   <TD><B>1995</B></TD>
   <TD><B>1996 </B></TD>
   <TD><B>1995</B></TD>
<TR>
   <TD><B>Total Revenues</B></TD>
   <TD ALIGN=right>$1,119</TD>
   <TD ALIGN=right>$617</TD>
   <TD ALIGN=right>$2,640</TD>
   <TD ALIGN=right>1,857</TD>
<TR>
   <TD><B>Net Loss</B></TD>
   <TD ALIGN=right>(1,120)</TD>
   <TD ALIGN=right>(1,952)</TD>
   <TD ALIGN=right>(3,577)</TD>
   <TD ALIGN=right>(8,670)*</TD>
<TR>
   <TD><B>Net Loss per Common Share</B></TD>
   <TD ALIGN=right>(.15)</TD>
   <TD ALIGN=right>(.25)</TD>
   <TD ALIGN=right>(.46)</TD>
   <TD ALIGN=right>(1.10)</TD>


<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TR>
   <TD><B>Summary of Net Loss by Corporate Entity: </B></TD>
   <TD></TD>
   <TD></TD>
   <TD></TD>
   <TD></TD>
<TR>
   <TD><B>CytRx Corporation </B></TD>
   <TD ALIGN=right> $(420)</TD>
   <TD ALIGN=right>$(1,566)</TD>
   <TD ALIGN=right>$(1,475)</TD>
   <TD ALIGN=right>$(6,955)</TD>
<TR>
   <TD><B>Proceutics, Inc.</B></TD>
   <TD ALIGN=right>(166)</TD>
   <TD ALIGN=right>-</TD>
   <TD ALIGN=right>(725)</TD>
   <TD ALIGN=right>-</TD>
<TR>
   <TD><B>Vaxcel, Inc. </B></TD>
   <TD ALIGN=right> (264)</TD>
   <TD ALIGN=right>(246)</TD>
   <TD ALIGN=right>(777)</TD>
   <TD ALIGN=right>(1,138)</TD>
<TR>
   <TD><B>Vetlife, Inc. </B></TD>
   <TD ALIGN=right>(270)</TD>
   <TD ALIGN=right>(140)</TD>
   <TD ALIGN=right>(600)</TD>
   <TD ALIGN=right>(577)</TD>
<TR>
   <TD> </TD>
   <TD ALIGN=right>-------- </TD>
  <TD ALIGN=right>--------</TD>
   <TD ALIGN=right>--------</TD>
   <TD ALIGN=right>--------</TD>
<TR>
   <TD><B>Net Loss </B></TD>
   <TD ALIGN=right> $(1,120)</TD>
   <TD ALIGN=right>$(1,952)</TD>
   <TD ALIGN=right>$(3,577)</TD>
   <TD ALIGN=right>$(8,670)</TD>
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TR>
<TD><B>Cash and Short-term Investments</B></TD>
<TD ALIGN=right> $19,392</TD>
<TD ALIGN=right> $27,099</TD>
<TD></TD>
<TR>
<TD><B>Common Shares Outstanding</B></TD>
<TD ALIGN=right> 7,587**</TD>
<TD ALIGN=right> 7,908</TD>
<TD></TD>
</TABLE>
</CENTER>


 

<P>
* Includes $1,103 of realized investment losses previously reflected
on the balance sheet as of December 31, 1994, and a charge of
$1,395 related to a change in the method of accounting for patent
costs.<BR>
** Net of 351 treasury shares.<BR>
<BR>

<P>
<BR>
<P>


<img src="/icons/rain_line.gif">	
<p>
<b>
[ <a href="/index.html">Home</a> 
| <a href="http://www.titermax.com">TiterMax</a> 
| <a href="/financial/overview.html">Investor Info</a> 
| <a href="/communications.html">Communications</a> 
| <a href="/adproceu.html">Proceutics</a>  
] </b>
<p>
</BODY>

</HTML>

</DOC>